
NOTE: This flow diagram represents an overview of population criteria requirements. Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.

#### Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <=40%)


Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior MI or a current or prior LVEF <=40% who were prescribed beta-blocker therapy

#### This eCQM is a patient-based measure




#### **Initial Population 1**


Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)




Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)



Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)





# eCQM Identifier: CMS145v12 NQF Number: 0070e eCQM Title: Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <=40%)

**NOTE:** This flow diagram represents an overview of population criteria requirements. Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.

**Description** Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior MI or a current or prior LVEF <=40% who were prescribed beta-blocker therapy.

# This eCQM is a patient-based measure.

# eCQM Flow Narrative

### **Initial Population 1**

Start by identifying the Initial Population 1, which includes patients 18 years of age and older with two eligible encounters during the measurement period and either a diagnosis of coronary artery disease that overlaps an eligible encounter or cardiac surgery before end of an eligible encounter.

### **Denominator 1**

The Denominator 1 criteria further constrain the Initial Population 1 to patients with current or prior moderate or severe Left Ventricular Systolic Disfunction (LVSD) (e.g., LVEF less than or equal to 40 percent or diagnosis of moderate or severe LVSD). In the sample calculation provided at the end of the eCQM flow, Denominator 1 is equal to 50 patients.

### Numerator 1

The Numerator 1 criteria identify a subset of the Denominator 1 population by including patients who were ordered beta-blocker therapy during an eligible encounter or patients who were actively taking beta-blocker therapy through the end of an eligible encounter. In the sample calculation provided at the end of the eCQM flow, Numerator 1 is equal to 25 patients.

### **Denominator Exceptions 1**

The Denominator Exceptions 1 criteria identify patients from the Denominator 1 that did not meet the Numerator 1 population criteria due to documentation of a medical reason(s) or patient reason(s) for not ordering beta-blocker therapy. In the sample calculation provided at the end of the eCQM flow, the Denominator Exceptions 1 are equal to 10 patients.

# **Initial Population 2**

Start by identifying the Initial Population 2, which includes patients 18 years of age and older with two eligible encounters during the measurement period and either a diagnosis of coronary artery disease that overlaps an eligible encounter or cardiac surgery before end of an encounter.

# **Denominator 2**

The Denominator 2 criteria further constrain the Initial Population 2 to patients with myocardial infarction (3 years or less before an eligible encounter). In the sample calculation provided at the end of the eCQM flow, Denominator 2 is equal to 50 patients.

# Numerator 2

The Numerator 2 criteria identify a subset of the Denominator 2 population by including patients who were ordered beta-blocker therapy during an eligible encounter or patients who were actively taking beta-blocker therapy through the end of an eligible encounter. In the sample calculation provided at the end of the eCQM flow, Numerator 2 is equal to 25 patients.

# **Denominator Exceptions 2**

The Denominator Exceptions 2 criteria identify patients from the Denominator 2 that did not meet the Numerator 2 population criteria due to documentation of a medical reason(s) or patient reason(s) for not ordering beta-blocker therapy. In the sample calculation provided at the end of the eCQM flow, the Denominator Exceptions 2 are equal to 10 patients.

### **Sample Calculation**

A sample calculation is provided to help determine how the measure performance rate is derived. The measure performance rate is calculated by summing Numerator 1 and Numerator 2 (total equals 50 patients) then dividing by the difference between the sum of Denominator 1 and Denominator 2 (total equals 100 patients) and the sum of Denominator Exceptions 1 and Denominator Exceptions 2 (total equals 20 patients), which is equal to a score of 63 percent.